Avalo Therapeutics (AVTX) CMO exercises options and sells 3,000 shares under plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Avalo Therapeutics Chief Medical Officer Mittie Doyle reported an exercise-and-sell transaction in Avalo Therapeutics, Inc. common stock. On May 15, 2026, she exercised stock options to acquire 3,000 shares of common stock at $12.65 per share, then sold 3,000 shares in an open-market transaction at $18.76 per share.
After these transactions, she directly holds 3,622 shares of common stock and 128,625 stock options. The filing states the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 3,000 shares ($56,280)
Net Sell
3 txns
Insider
Doyle Mittie
Role
Chief Medical Officer
Sold
3,000 shs ($56K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 3,000 | $0.00 | -- |
| Exercise | Common Stock | 3,000 | $12.65 | $38K |
| Sale | Common Stock | 3,000 | $18.76 | $56K |
Holdings After Transaction:
Stock Option (Right to Buy) — 128,625 shares (Direct, null);
Common Stock — 6,622 shares (Direct, null)
Footnotes (1)
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Shares sold: 3,000 shares
Sale price: $18.76 per share
Option exercise price: $12.65 per share
+3 more
6 metrics
Shares sold
3,000 shares
Open-market sale of common stock on May 15, 2026 at $18.76
Sale price
$18.76 per share
Price for 3,000 common shares sold on May 15, 2026
Option exercise price
$12.65 per share
Exercise price for 3,000 stock option shares converted to common
Common shares after transaction
3,622 shares
Direct common stock holdings following the reported transactions
Remaining stock options
128,625 options
Stock options outstanding after 3,000-share exercise; expire July 15, 2034
Rule 10b5-1 plan adoption date
November 13, 2025
Date the trading plan governing these transactions was adopted
Key Terms
Rule 10b5-1 trading plan, Stock Option (Right to Buy), open-market sale, derivative exercise/conversion, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"transactions were effected pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with underlying common stock"
open-market sale financial
"transaction_action: "open-market sale" for 3,000 common shares at $18.76"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative exercise/conversion financial
"transaction_action: "derivative exercise/conversion" for 3,000 underlying shares"
expiration date financial
"stock option shows an expiration date of 2034-07-15 for remaining options"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What insider transaction did Avalo Therapeutics (AVTX) report for Mittie Doyle?
Avalo Therapeutics reported that Chief Medical Officer Mittie Doyle exercised options for 3,000 shares and sold 3,000 shares of common stock on May 15, 2026. This reflects an exercise-and-sell pattern rather than a simple open-market purchase or sale.
Were Mittie Doyle’s Avalo Therapeutics (AVTX) trades made under a Rule 10b5-1 plan?
Yes. The Form 4 states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Such pre-arranged plans automate trading, reducing the significance of trade timing as an indicator of insider sentiment.
What type of options did Mittie Doyle exercise in the Avalo Therapeutics (AVTX) Form 4?
She exercised a stock option described as a “Stock Option (Right to Buy)” covering 3,000 underlying common shares at a $12.65 exercise price. After this exercise, 128,625 option shares remain outstanding with an expiration date of July 15, 2034.